PartitionBio is a start-up R&D company that is active in the biotechnology & pharma sectors. The company has been operating since 2022 and is incorporated as a private limited company in the UK. PartitionBio has its offices and laboratories on the Chesterford Research Park near Cambridge, and currently employs 9 full-time staff. The past decade has seen an explosion of scientific insight into the role that biomolecular condensates play in biology, as well as into the physicochemical principles underlying their formation by liquid-liquid-phase-separation (LLPS) of biomolecules. PartitionBio’s vision is to translate this emerging understanding into novel biomedical applications, particularly in the therapeutics space. The company’s initial focus is on the identification of formulations that generate biomolecular condensates capable of enriching drug cargos and of delivering them across the membranes of target cells. The company is transforming its recent discoveries in this area into a platform approach for the delivery of hard-to-deliver therapeutics (specifically large biology drugs) in a clinical context.